Plain-language summary

This study is testing Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

• Age 18 Years to 65 Years years
• Lymphoma came back or did not respond to prior treatment
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation (OTHER): Drug: Pralatrexate, Chidamide 1. Pralatrexate: 30 mg/m2 intravenously (IV) administered weekly in 6-week cycles. Chidamide: 20mg, twice a week in 3-week cycles (2 weeks on treatment, 1 week off treatment) 2. After the 6-week therapy, the patients should receive PET/CT evaluation. 3. Patients would receive allo-HSCT if they could achieve at least PR after the first cycle of therapy. For the patients could not achieve a least PR after the first cycle of therapy, they should receive a second cycle of pralatrexate combined with chidamide. The interval between two cycles of pralatrexate combined with chidamide should be at least 1 week. 4. After the second cycle of 6-week therapy, the patients should receive PET/CT evaluation. Patients would receive allo-HSCT if they could achieve at least SD after the second cycle of therapy. For the patients could not achieve a least SD after the second cycle of therapy, they should receive other salvage therapies.

Drugs / treatments

Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details